Pharmacological therapies for Angelman syndrome; [Pharmakologische Therapien bei Angelman-Syndrom]

被引：9
作者：
Tan W.-H. [1 ]
Bird L.M. [3 ,4 ]
机构：
[1] Harvard Medical School, Boston, MA
[2] Department of Pediatrics, University of California, San Diego, CA
[3] Division of Genetics/Dysmorphology, Rady Children’s Hospital San Diego, 3020 Children’s Way, # 5031, San Diego, 92123, CA
来源：
Wiener Medizinische Wochenschrift | 2017年 / 167卷 / 9-10期
关键词：
Angelman syndrome; Clinical trial; Mouse model; Therapeutic; Therapy;
D O I：
10.1007/s10354-015-0408-z
中图分类号：
学科分类号：
摘要：
Angelman syndrome (AS) is a severe neurodevelopmental disorder caused by a loss of the maternally inherited UBE3A; the paternal UBE3A is silenced in neurons by a mechanism involving an antisense transcript (UBE3A-AS). We reviewed the published information on clinical trials that have been completed as well as the publicly available information on ongoing trials of therapies for AS. Attempts at hypermethylating the maternal locus through dietary compounds were ineffective. The results of a clinical trial using minocycline as a matrix metalloproteinase-9 inhibitor were inconclusive; another clinical trial is underway. Findings from a clinical trial using L-dopa to alter phosphorylation of calcium/calmodulin-dependent kinase II are awaited. Topoisomerase inhibitors and antisense oligonucleotides are being developed to directly inhibit UBE3A-AS. Other strategies targeting specific pathways are briefly discussed. We also reviewed the medications that are currently used to treat seizures and sleep disturbances, which are two of the more debilitating manifestations of AS. © 2015, Springer-Verlag Wien.
引用
收藏
页码：205 / 218
页数：13
相关论文
共 117 条
[1]  
Thibert R.L., Larson A.M., Hsieh D.T., Et al., Neurologic manifestations of Angelman syndrome, Pediatr Neurol, 48, pp. 271-279, (2013)
[2]  
Bird L.M., Angelman syndrome: review of clinical and molecular aspects, Appl Clin Genet, 7, pp. 93-104, (2014)
[3]  
Larson A.M., Shinnick J.E., Shaaya E.A., Et al., Angelman syndrome in adulthood, Am J Med Genet A, 167 A, pp. 331-344, (2015)
[4]  
Williams C.A., Beaudet A.L., Clayton-Smith J., Et al., Angelman syndrome 2005: updated consensus for diagnostic criteria, Am J Med Genet A, 140, pp. 413-418, (2006)
[5]  
Dagli A., Buiting K., Williams C.A., Molecular and clinical aspects of Angelman syndrome, Mol Syndromol, 2, pp. 100-112, (2012)
[6]  
Low D., Chen K.S., Genome-wide gene expression profiling of the Angelman syndrome mice with Ube3a mutation, Eur J Hum Genet, 18, pp. 1228-1235, (2010)
[7]  
Jensen L., Farook M.F., Reiter L.T., Proteomic profiling in Drosophila reveals potential Dube3a regulation of the actin cytoskeleton and neuronal homeostasis, PLoS One, 8, (2013)
[8]  
Buiting K., Lich C., Cottrell S., Et al., A 5-kb imprinting center deletion in a family with Angelman syndrome reduces the shortest region of deletion overlap to 880 bp, Hum Genet, 105, pp. 665-666, (1999)
[9]  
Dubose A.J., Smith E.Y., Yang T.P., Et al., A new deletion refines the boundaries of the murine Prader–Willi syndrome imprinting center, Hum Mol Genet, 20, pp. 3461-3466, (2011)
[10]  
Dittrich B., Buiting K., Korn B., Et al., Imprint switching on human chromosome 15 may involve alternative transcripts of the SNRPN gene, Nat Genet, 14, pp. 163-170, (1996)
12345678910